
Julie Kim to Succeed Christophe Weber as CEO of Takeda
Takeda has appointed Julie Kim, currently president of the company’s US business unit, to succeed Christophe Weber as CEO in June 2026, who will retire after 12 years in this role.
Takeda has appointed Julie Kim, currently president of the company’s US business unit, to succeed Christophe Weber as CEO in June 2026, who will retire after 12 years in this role.
Industry experts Michelangelo Canzoneri, Josef Trapl, Wolfgang Winter, Christian Woelbeling, and Thomas Zimmer – all members of ISPE’s Pharma 4.0 guide core team – explain the transformational challenges and critical success factors of the digital Pharma 4.0 journey.
Novartis has signed an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. The transaction is valued at up to $2.5 billion, which marks a strategic move to focus on innovative medicines and growth opportunities.
Japanese drugmaker Takeda plans to invest about $765 million to build a new manufacturing facility in Osaka for plasma-derived therapies (PDTs). The company said the sum is the largest-ever investment to expand capacity in Japan and the plant will also be the biggest of its kind in the country.
Japanese pharma Takeda is acquiring Nimbus Lakshmi, a wholly-owned subsidiary of US clinical-stage drug discovery company Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858, which is undergoing trials for treating multiple autoimmune diseases, including psoriasis.
The International Society for Pharmaceutical Engineering (ISPE) has announced Takeda Pharmaceuticals International as the 2022 Facility of the Year Awards (FOYA) Overall Winner.
Following a multi-year collaboration, Japanese pharma Takeda has exercised its option to buy the UK’s GammaDelta Therapeutics for a pre-negotiated upfront sum, as well as future potential development and regulatory milestone payments. Takeda expects the acquisition to be finalized during the first quarter of its 2022 fiscal year.
Japanese drugmaker Takeda has clarified its plans to produce and distribute the Novavax Covid-19 shot in the country, if and when it is approved. After several delays, in its last announcement the US biotech said it planned to apply to the US Food and Drug Administration (FDA) for Emergency Use Authorization in this year’s fourth quarter.
Industry experts Josef Trapl, Wolfgang Winter, Christian Woelbeling, and Thomas Zimmer – all members of ISPE’s Pharma 4.0 group – talk about the idea behind ISPE’s Pharma 4.0 initiative and the challenges on the way to realize the digital transformation of the pharmaceutical industry.
The question of what kind of particulate matter found its way into vials of Moderna’s Covid-19 vaccine deployed in Japan may have been resolved. There is as yet indication that contaminated doses may have caused the deaths of two men who had received the US biotech’s shot days earlier.
The International Society for Pharmaceutical Engineering (ISPE) announced the 2021 Facility of the Year Awards (FOYA) Category Winners—including two winners of Special Recognition Awards for Operational Agility: Covid-19 Impact.
US vaccine manufacturer Moderna has tapped Takeda as marketing partner for its Covid-19 vaccine candidate mRNA-1273f in Japan. Financial terms of the deal were not disclosed. The Japanese drugmaker will import and distribute the vaccine starting in the first half of next year as well as handle local regulatory approvals. The original contract is for 50 million doses.
As rumored earlier this month, private equity group Blackstone has emerged as the winning bidder for Takeda’s consumer healthcare business. The transaction is expected to close by Mar. 31, 2021, subject to the usual closing conditions and regulatory approvals.
Japanese pharma Takeda is apparently winding down the asset-shedding drive it launched following the $59 billion acquisition of Shire. The company is currently said to be in talks to sell its domestic consumer health (OTC) business to US private equity investor Blackstone.